Indaptus Therapeutics is a clinical-stage biotechnology company developing a bacteria-based immunotherapy platform called Decoy. Its candidates use attenuated, killed non-pathogenic Gram-negative bacteria designed to activate broad innate and adaptive immune pathways after intravenous dosing, in an antigen-agnostic way. Lead product Decoy20 is being studied in solid tumors, including combinations with checkpoint inhibitors, with broader interest in oncology and certain viral infections.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -5.2 | — |
| Q3 2025 | 0 | — | -3 | — |
| Q4 2025 | 0 | — | -8.1 | — |
| Q1 2026 | 0 | — | -2.5 | — |
| Q2 2026 | 0 | — | -1.8 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Fennec Pharmaceuticals Inc. (FENC), Vox Royalty Corp. (VOXR), Soren Acquisition Corp. (SORN), BlackRock TCP Capital Corp. (TCPC), Einride AB (ENRD), CapsoVision, Inc. (CV)